Marburg virus disease - Pipeline Insight, 2024

This “Marburg virus disease - Pipeline Insight, 2024,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Marburg virus disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Marburg virus disease Understanding

Marburg virus disease: Overview

Marburg virus disease is a highly virulent disease that causes haemorrhagic fever, with a fatality ratio of up to 88%. It is in the same family as the virus that causes Ebola virus disease. Human infection with Marburg virus disease initially results from prolonged exposure to mines or caves inhabited by Rousettus bat colonies. Once an individual is infected with the virus, Marburg can spread through human-to-human transmission via direct contact (through broken skin or mucous membranes) with the blood, secretions, organs or other bodily fluids of infected people, and with surfaces and materials (e.g. bedding, clothing) contaminated with these fluids.

Marburg virus disease - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Marburg virus disease pipeline landscape is provided which includes the disease overview and Marburg virus disease treatment guidelines. The assessment part of the report embraces, in depth Marburg virus disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Marburg virus disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Marburg virus disease R&D. The therapies under development are focused on novel approaches to treat/improve Marburg virus disease.

Marburg virus disease Emerging Drugs Chapters

This segment of the Marburg virus disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Marburg virus disease Emerging Drugs

Galidesivir: Bio Cryst Pharmaceuticals Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses that pose a threat to health and national security, including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika. BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions. In September 2013, NIAID contracted with BioCryst for the development of galidesivir as a treatment for Marburg virus disease and potentially for other filoviruses, including Ebola virus. The drug is currently in phase 1 stage of clinical trial evaluation for the treatment of Marburg virusdisease.

MVA-BN filovirus vaccine: Bavarian Nordic MVA-BN Filo is a multivalent vaccine candidate designed to provide protection against the most common causes of viral hemorrhagic fever; Ebola and Marburg virus. While several sub-types of Ebola are known, our vaccine is targeting the Zaire and Sudan strains, which are considered the most important from a public health perspective. It is currentl;y in phase 2 stage of clinical trial evaluation for the treatment of Marburg virusdisease.

Marburg virus disease: Therapeutic Assessment

This segment of the report provides insights about the different Marburg virus disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Marburg virus disease

There are approx. 12+ key companies which are developing the therapies for Marburg virus disease. The companies which have their Marburg virus disease drug candidates in the most advanced stage, i.e. phase II include, Bavarian Nordic.

Phases

This report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Marburg virus disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Marburg virus disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Marburg virus disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Marburg virus disease drugs.

Marburg virus disease Report Insights

• Marburg virus disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Marburg virus disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Marburg virus disease drugs?
• How many Marburg virus disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Marburg virus disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Marburg virus disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Marburg virus disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Bio CrystPharmaceuticals
• Bavarian Nordic
• Flow Pharma
• AlphaVax
• Emergex Vaccines
• ReiThera
• Globavir Biosciences
• Mapp Biopharmaceutical
• Collaborations Pharmaceuticals, Inc.
• Emergent Bio SolutionsInc.
• Auro Vaccines
• Alkido Pharma
• Biofactura

Key Products

• Galidesivir
• MVA-BN filovirus vaccine
• Marburg vaccine
• r VSV Marburg virusvaccine

Research programme: biodefence vaccines- Research programme: filovirus vaccine

• VRC MARADC087 00 VP
• GBV 006
• MBP 091

This product will be delivered within 1-3 business days.